{"url_path":"/sec/slxnw/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002805-index.html","accession_number":"0001178913-26-002805","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002805-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":1026,"has_tables":true,"body_markdown":"Silexion Therapeutics Corp - 2022416 - 2026\n\ntrueFY000202241600-0000000\n\n0002022416\n2025-01-01\n2025-12-31\n\n0002022416us-gaap:CommonStockMember\n2025-01-01\n2025-12-31\n\n0002022416slxn:WarrantsExercisableForOrdinarySharesMember\n2025-01-01\n2025-12-31\n\n0002022416\n2026-03-10\n\n0002022416\n2025-06-30\nxbrli:shares\niso4217:USD\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\nFORM 10-K/A\n\nAmendment No. 1\n\n \n\n☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES\n\nEXCHANGE ACT OF 1934\n\n \n\nFor the fiscal year ended December 31, 2025\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES\n\nEXCHANGE ACT OF 1934\n\n \n\nFor the transition period from _______________ to _______________\n\n \n\nCommission File Number 001-39157\n\n \n\n \n\nSilexion Therapeutics Corp\n\n(Exact name of registrant as specified in its charter)\n\n \n\nCayman Islands\n\n \n\n001-42253\n\n \n\nN/A\n\n(State or other jurisdiction\n\nof incorporation)\n\n \n\n(Commission File Number)\n\n \n\n(IRS Employer\nIdentification No.)\n\n \n\n12 Abba Hillel Road\nRamat-Gan, Israel 5250606\n\n(Address of principal executive offices, including zip code)\n\n \n\nRegistrant’s telephone number, including area code: +972-3 756-4999\n\n \n\nNot Applicable \n\n(Former name or former address, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbol(s)\n\n \n\nName of each exchange on\nwhich registered\n\nOrdinary shares, par value $0.0135 per share\n\n \n\nSLXN\n\n \n\nThe Nasdaq Stock Market LLC\n\nWarrants exercisable for ordinary shares at an exercise price of $1,552.50 per share \n\n \n\nSLXNW \n\n \n\nThe Nasdaq Stock Market LLC\n\n \n\nSecurities registered pursuant to Section 12(g) of the Act: None\n\n \n\n \n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.\n\n \n\nYes ☐    No ☒\n\n \n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.\n\n \n\nYes ☐    No ☒\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\n \n\nYes ☒    No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\n \n\nYes ☒    No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☒\n\n \n\n \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\n\n \n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\n \n\nYes ☐       No ☒\n\n \n\nAs of June 30, 2025 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s ordinary shares held by non-affiliates (based on 8,172,750 ordinary shares held by non-affiliates as of that date and an $0.81 closing price of the ordinary shares on Nasdaq on that date (neither of which reflects the subsequent 1-for-15 reverse share split effected by the registrant on July 29, 2025) was $6,619,600.\n\n \n\nAs of March 10, 2026, 3,330,785 ordinary shares, par value $0.0135 per share, were issued and outstanding.\n\n \n\nDocuments Incorporated by Reference: None.\n\n \n\n \n\nEXPLANATORY NOTE\n\n \n\nThis Amendment No. 1 on Form 10-K/A (this “Amendment”) to the Annual Report on Form 10-K of Silexion Therapeutics Corp (the “Company”, “we”, “us” or “our”) for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2026 (the “Original 10-K”), is being filed solely to amend and restate Part II “Item 9A. Controls and Procedures” to correct typographical errors whereby the date as of which the Company’s management evaluated the effectiveness of our internal control over financial reporting is stated as December 31, 2024 whereas that evaluation was actually carried out as of December 31, 2025. Those typographical errors are corrected in this Amendment.\n\n \n\nThis Amendment contains only the cover page, this explanatory note, the complete text of Item 9A, the exhibit list, a signature page and the certifications of the Company’s principal executive and financial and accounting officers under the Sarbanes Oxley Act of 2002, as amended.\n\n \n\nOther than as expressly set forth herein (including updated versions of Exhibits 3.5 and 10.5.2 listed in the exhibit index, which reflect updated versions of matters included in the Original 10-K that have been approved by our shareholders since the filing of the Original 10-K), this Amendment does not, and does not purport to, amend, update or restate the information in the Original 10-K or reflect any events that have occurred after the Original 10-K was filed. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original 10-K was filed. This Amendment should be read together with the Original 10-K and the Company’s other filings with the SEC."}